Episodes

Tuesday Jan 19, 2021
Contraception in the Era of CFTR Modulators
Tuesday Jan 19, 2021
Tuesday Jan 19, 2021
On Tuesday July 21, 2020, CFRI hosted a webinar on Contraception in the Era of CFTR Modulators. Emily Godfrey, MD, MPH (University of Washington), Patricia Walker, MD (Mount Sinai Beth Israel, NY), Molly Pam and Laura Mentch (women with CF) discussed the epidemiology of unplanned pregnancy and contraceptive need among women with CF; how hormonal contraception may affect CF disease; and contraceptive considerations in the era of CFTR modulators.
CF Community Voices is sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA and Mylan Pharmaceuticals.

Tuesday Jan 19, 2021
Bringing Patient Centered Outcomes Research to the CF Community
Tuesday Jan 19, 2021
Tuesday Jan 19, 2021
The vital impact of patient centered outcomes research is increasingly understood. Emily Godfrey, MD, MPH, Associate Professor in the Departments of Family Medicine and Obstetrics and Gynecology at the University of Washington, and Laura Mentch, adult with CF and patient-partner with the Cystic Fibrosis Reproductive and Sexual Health Collaborative (CFReSHC), share their expertise and experience in bringing patient centered outcomes research to the CF community.
We thank our sponsors, Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA and Mylan Pharmaceuticals.

Tuesday Jan 19, 2021
Greet Me Germ Free - The Update
Tuesday Jan 19, 2021
Tuesday Jan 19, 2021
We thank Vertex Pharmaceuticals, Gilead Sciences, Genentech, Chiesi USA, and Mylan Pharmaceuticals for their support of these podcasts.

Tuesday Jan 19, 2021
COVID-19 and Cystic Fibrosis: Q&A Session #11 with Rick Moss, MD - June 24, 2020
Tuesday Jan 19, 2021
Tuesday Jan 19, 2021
Rick Moss, MD, CF clinician and researcher at Stanford, answers CF and COVID-19-related questions submitted by our community over the past week related to antibody tests, impacts on those with CF, and much more. This session was recorded on June 24, 2020.
We thank Vertex Pharmaceuticals, Gilead Sciences, Genentech, and Chiesi USA for their support of these podcasts.
Track: Woods Artist: Federico Fabbiano Music provided by Oak Studios https://youtu.be/eAiAlg22gqQ

Wednesday Jan 13, 2021
COVID-19, Cystic Fibrosis & Vaccines: Q & A with Richard Moss, MD
Wednesday Jan 13, 2021
Wednesday Jan 13, 2021
On January 7, 2021, CFRI hosted a webinar with Dr. Rick Moss, CF clinician and researcher at Stanford. Dr. Moss gave an overview of the current state of the pandemic - including its impact upon those with cystic fibrosis - and answered questions from the CF community with a focus on vaccines.
CF Community Voices is sponsored to date by Chiesi USA.
If you watch this podcast episode, please let us know what you think at https://www.surveymonkey.com/r/TMRP766

Wednesday Jan 13, 2021
COVID-19, Cystic Fibrosis & Vaccines: Q & A with Richard Moss, MD
Wednesday Jan 13, 2021
Wednesday Jan 13, 2021
On January 7, 2021, CFRI hosted a webinar with Dr. Rick Moss, CF clinician and researcher at Stanford. Dr. Moss gave an overview of the current state of the pandemic - including its impact upon those with cystic fibrosis - and answered questions from the CF community with a focus on vaccines.
CF Community Voices is sponsored to date by Chiesi USA.
If you watch this podcast episode, please let us know what you think at https://www.surveymonkey.com/r/TMRP766

Wednesday Dec 09, 2020
A Review of Lenabasum Phase II Clinical Trial Results - James Chmiel, MD, MPH (Audio)
Wednesday Dec 09, 2020
Wednesday Dec 09, 2020
The role of anti-inflammatories in CF care is vital. Lenabasum, Corbus Pharmaceuticals' investigational drug that mimics the effects of endocannabinoids in regulating inflammation, has been tracked through the clinical trial process with tremendous optimism. Dr. Chmiel, Principal Investigator of CF-002 (lenabasum), and Division Chief for Pediatric Pulmonology, Allergy and Sleep Medicine at Indiana University School of Medicine, reviews the results of the recent Phase IIb trial, and its implications for the CF community.
Sponsored by Vertex Pharmaceuticals, Gilead Sciences, Chiesi USA, Genentech, and Viatris, with additional support from Corbus Pharmaceuticals.

Wednesday Dec 09, 2020
A Review of Lenabasum Phase II Clinical Trial Results - James Chmiel, MD, MPH
Wednesday Dec 09, 2020
Wednesday Dec 09, 2020
The role of anti-inflammatories in CF care is vital. Lenabasum, Corbus Pharmaceuticals' investigational drug that mimics the effects of endocannabinoids in regulating inflammation, has been tracked through the clinical trial process with tremendous optimism. Dr. Chmiel, Principal Investigator of CF-002 (lenabasum), and Division Chief for Pediatric Pulmonology, Allergy and Sleep Medicine at Indiana University School of Medicine, reviews the results of the recent Phase IIb trial, and its implications for the CF community.
Sponsored by Vertex Pharmaceuticals, Gilead Sciences, Chiesi USA, Genentech, and Viatris, with additional support from Corbus Pharmaceuticals.

Thursday Jun 25, 2020
Greet Me Germ Free - The Update
Thursday Jun 25, 2020
Thursday Jun 25, 2020
We thank Vertex Pharmaceuticals, Gilead Sciences, Genentech, Chiesi USA, and Mylan Pharmaceuticals for their support of these podcasts.

Wednesday Jun 24, 2020
COVID-19 and Cystic Fibrosis: Q&A Session #11 with Rick Moss, MD - June 24, 2020
Wednesday Jun 24, 2020
Wednesday Jun 24, 2020
Rick Moss, MD, CF clinician and researcher at Stanford, answers CF and COVID-19-related questions submitted by our community over the past week related to antibody tests, impacts on those with CF, and much more. This session was recorded on June 24, 2020.
We thank Vertex Pharmaceuticals, Gilead Sciences, Genentech, and Chiesi USA for their support of these podcasts.
Track: Woods Artist: Federico Fabbiano Music provided by Oak Studios https://youtu.be/eAiAlg22gqQ

